tiprankstipranks
Advertisement
Advertisement

KHTRF Stock Latest News

Knight Therapeutics price target raised to C$8.50 from C$8 at RBC Capital
The FlyKnight Therapeutics price target raised to C$8.50 from C$8 at RBC Capital
4d ago
Knight Therapeutics Posts Record 2025 Revenue, Sets Confident 2026 Outlook
PremiumCompany Announcements
Knight Therapeutics Posts Record 2025 Revenue, Sets Confident 2026 Outlook
5d ago
Knight Therapeutics sees FY26 revenue C$490M-C$510M
PremiumThe Fly
Knight Therapeutics sees FY26 revenue C$490M-C$510M
5d ago
Knight Therapeutics reports Q4 EPS C$0.09 vs. C$0.11 last year
PremiumThe Fly
Knight Therapeutics reports Q4 EPS C$0.09 vs. C$0.11 last year
5d ago
Knight Therapeutics sumbits supplemental MINJUVI application to ANMAT, COFEPRIS
PremiumThe Fly
Knight Therapeutics sumbits supplemental MINJUVI application to ANMAT, COFEPRIS
7d ago
INCY
Knight announces approval of additional MINJUVI indication in Brazil
PremiumThe FlyKnight announces approval of additional MINJUVI indication in Brazil
7d ago
KHTRF Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
KHTRF Upcoming Earnings Report: What to Expect?
7d ago
Knight Therapeutics announces NIKTIMVO regulatory submission in Brazil
Premium
The Fly
Knight Therapeutics announces NIKTIMVO regulatory submission in Brazil
1M ago
INCY
Knight Therapeutics announces Health Canada approval for WYNZORA
PremiumThe Fly
Knight Therapeutics announces Health Canada approval for WYNZORA
3M ago
Knight Therapeutics Reports Record Revenues Amid Challenges
PremiumCompany Announcements
Knight Therapeutics Reports Record Revenues Amid Challenges
5M ago
Knight Therapeutics Reports Record Q3 Revenues and Raises Guidance
PremiumCompany Announcements
Knight Therapeutics Reports Record Q3 Revenues and Raises Guidance
5M ago
Knight Therapeutics Achieves Record-High Revenues in Q3 2025
PremiumCompany Announcements
Knight Therapeutics Achieves Record-High Revenues in Q3 2025
5M ago
Knight Therapeutics reports Q3 EPS (C$0.04) vs. (C$0.00) last year
PremiumThe FlyKnight Therapeutics reports Q3 EPS (C$0.04) vs. (C$0.00) last year
5M ago
Knight Therapeutics sees FY25 revenue C$430M-C$440M
Premium
The Fly
Knight Therapeutics sees FY25 revenue C$430M-C$440M
5M ago
Knight Therapeutics (KHTRF) Q3 Earnings Cheat Sheet
Premium
Pre-Earnings
Knight Therapeutics (KHTRF) Q3 Earnings Cheat Sheet
5M ago
Knight Therapeutics Secures US$100 Million Credit Facility to Boost Growth
PremiumCompany Announcements
Knight Therapeutics Secures US$100 Million Credit Facility to Boost Growth
5M ago
Knight Therapeutics announces approval, launch of MINJUVI in Argentina
PremiumThe Fly
Knight Therapeutics announces approval, launch of MINJUVI in Argentina
5M ago
INCY
Knight Therapeutics announces relaunch of MYFEMBREE in Canada
PremiumThe Fly
Knight Therapeutics announces relaunch of MYFEMBREE in Canada
6M ago
Knight Therapeutics announces relaunch of ORGOVYX in Canada
PremiumThe Fly
Knight Therapeutics announces relaunch of ORGOVYX in Canada
6M ago
Knight Therapeutics announces normal course issuer bid
PremiumThe FlyKnight Therapeutics announces normal course issuer bid
7M ago
Knight Therapeutics’ Earnings Call Highlights Growth and Expansion
Premium
Company Announcements
Knight Therapeutics’ Earnings Call Highlights Growth and Expansion
7M ago
Knight Therapeutics: Strong Financial Performance and Strategic Positioning Justify Buy Rating
Premium
Ratings
Knight Therapeutics: Strong Financial Performance and Strategic Positioning Justify Buy Rating
8M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >